Download PDF
Lege artis - Das Magazin zur ärztlichen Weiterbildung 2013; 3(2): 88-95
DOI: 10.1055/s-0033-1343876
Fachwissen
Titelthema: Krebsvorsorge
© Georg Thieme Verlag Stuttgart · New York

Krebsvorsorge – Blasen-, Nieren- und Hodenkarzinom

Tilman Todenhöfer
,
Johannes Mischinger
,
Stephan Kruck
,
Christian Schwentner
,
Jens Bedke
,
Arnulf Stenzl
Further Information

Publication History

Publication Date:
16 May 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Für die Früherkennung von Tumoren der Harnblase, Niere und Hoden gibt es effektive Untersuchungsmethoden. Besonders bei Risikopatienten sollte man diese regelmäßig anwenden und somit die Diagnose eines Tumors im Frühstadium ermöglichen. Allerdings konnte bisher nicht nachgewiesen werden, dass routinemäßige Vorsorgeuntersuchungen für Blasen-, Nieren- und Hodentumoren die tumorbedingte Mortalität signifikant reduzieren.

Kernaussagen

  • Jede urologische Vorsorgeuntersuchung sollte für die Identifikation von Risikofaktoren eine Familien- und Sozialanamnese beinhalten.

  • Eine persistierende Mikrohämaturie ohne Anzeichen einer nephrologischen Erkrankung bedarf einer genauen urologischen Abklärung.

  • Die Urinzytologie hat nur eine eingeschränkte Sensitivität für die Identifikation von Urothelkarzinomen.

  • Neue Urinmarker für das Blasenkarzinom (NMP22, FISH, Immunzytologie) sind sensitiver, verursachen jedoch mehr falsch positive Tests.

  • Zufällig entdeckte Nierenzysten sind häufig und sollten bei komplizierenden Faktoren (Septen, Binnenechos, Verkalkungen) durch ein 4-Phasen-Kontrastmittel-CT abgeklärt werden.

  • Patienten mit genetischen Syndromen und einem erhöhten Risiko für Nierentumoren muss ein regelmäßiges Screening empfohlen werden.

  • Die Selbstpalpation ist die effektivste Vorsorge für einen Hodentumor.

Schlüsselwörter

Blasenkarzinom - Nierenkarzinom - Hodenkarzinom - Früherkennung

Ergänzendes Material

 

  • 1 Jemal A, Bray F, Center MM et al. Global cancer statistics. CA: a cancer journal for clinicians 2011; 61: 69-90
    CrossrefGoogle Scholar
  • 2 Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World journal of urology 2009; 27: 289-293
    CrossrefGoogle Scholar
  • 3 Castelao JE, Yuan JM, Skipper PL et al. Gender- and smoking-related bladder cancer risk. Journal of the National Cancer Institute 2001; 93: 538-545
    CrossrefGoogle Scholar
  • 4 Dillman JR, Caoili EM, Cohan RH et al. Detection of upper tract urothelial neoplasms: sensitivity of axial, coronal reformatted, and curved-planar reformatted image-types utilizing 16-row multi-detector CT urography. Abdominal imaging 2008; 33: 707-716
    CrossrefGoogle Scholar
  • 5 Woolhandler S, Pels RJ, Bor DH et al. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA 1989; 262: 1214-1219
    CrossrefGoogle Scholar
  • 6 Wollin T, Laroche B, Psooy K. Canadian guidelines for the management of asymptomatic microscopic hematuria in adults. Canadian Urological Association journal 2009; 3: 77-80
    Google Scholar
  • 7 Grossfeld GD, Wolf Jr. JS, Litwan MS et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. American family physician 2001; 63: 1145-1154
    Google Scholar
  • 8 Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Canadian Urological Association journal 2008; 2: 212-221
    Google Scholar
  • 9 Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. European urology 2011; 59: 997-1008
    CrossrefGoogle Scholar
  • 10 Bubendorf L, Grilli B, Sauter G et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. American journal of clinical pathology 2001; 116: 79-86
    CrossrefGoogle Scholar
  • 11 Cha EK, Tirsar LA, Schwentner C et al. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. European urology 2012; 61: 185-192
    CrossrefGoogle Scholar
  • 12 Sanchez-Carbayo M, Urrutia M, Silva JM et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. The Journal of urology 2001; 165: 1462-1467
    CrossrefGoogle Scholar
  • 13 Todenhofer T, Hennenlotter J, Kuhs U et al. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer. Urology 2012; 79: 620-624
    CrossrefGoogle Scholar
  • 14 Todenhofer T, Hennenlotter J, Tews V et al. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urologic oncology [Epub ahead of print] 28.11.2011;
    Google Scholar
  • 15 Messing EM, Madeb R, Young T et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006; 107: 2173-2179
    CrossrefGoogle Scholar
  • 16 Mayfield MP, Whelan P. Bladder tumours detected on screening: results at 7 years. British journal of urology 1998; 82: 825-828
    CrossrefGoogle Scholar
  • 17 Hedelin H, Jonsson K, Salomonsson K, Boman H. Screening for bladder tumours in men aged 60–70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy. Scandinavian journal of urology and nephrology 2006; 40: 26-30
    CrossrefGoogle Scholar
  • 18 Lotan Y, Elias K, Svatek RS et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. The Journal of urology discussion 2009; 182
    Google Scholar
  • 19 Huber S, Schwentner C, Taeger D et al. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU international 2012; 110: 699-708
    CrossrefGoogle Scholar
  • 20 Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer 2010; 127: 2893-2917
    CrossrefGoogle Scholar
  • 21 Ljungberg B, Campbell SC, Choi HY et al. The epidemiology of renal cell carcinoma. European urology 2011; 60: 615-621
    CrossrefGoogle Scholar
  • 22 Chow WH, Gridley G, Fraumeni Jr. JF, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. The New England journal of medicine 2000; 343: 1305-1311
    CrossrefGoogle Scholar
  • 23 Kutikov A, Fossett LK, Ramchandani P et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology 2006; 68: 737-740
    CrossrefGoogle Scholar
  • 24 Bedke J, Buse S, Kurosch M et al. [Paraneoplastic syndrome in renal cell carcinoma]. Der Urologe Ausg A 2007; 46: 45-48
    CrossrefGoogle Scholar
  • 25 Todenhofer T, Wirths S, von Weyhern CH et al. Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma. BMC urology 2012; 12: 7-7
    CrossrefGoogle Scholar
  • 26 Jamis-Dow CA, Choyke PL, Jennings SB et al. Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 1996; 198: 785-788
    CrossrefGoogle Scholar
  • 27 Ravine D, Gibson RN, Donlan J, Sheffield LJ. An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases. American journal of kidney diseases : the official journal of the National Kidney Foundation 1993; 22: 803-807
    Google Scholar
  • 28 Remzi M, Marberger M. Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how?. European urology 2009; 55: 359-367
    CrossrefGoogle Scholar
  • 29 Mihara S, Kuroda K, Yoshioka R, Koyama W. Early detection of renal cell carcinoma by ultrasonographic screening--based on the results of 13 years screening in Japan. Ultrasound in medicine & biology 1999; 25: 1033-1039
    CrossrefGoogle Scholar
  • 30 Tosaka A, Ohya K, Yamada K et al. Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography. The Journal of urology 1990; 144: 1097-1099
    Google Scholar
  • 31 Tsuboi N, Horiuchi K, Kimura G et al. Renal masses detected by general health checkup. International journal of urology: official journal of the Japanese Urological Association 2000; 7: 404-408
    CrossrefGoogle Scholar
  • 32 Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. The Journal of urology 2003; 170: 2163-2172
    CrossrefGoogle Scholar
  • 33 Frantzen C, Links TP, Giles RH. Von Hippel-Lindau Disease. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP. eds. Seattle (WA): GeneReviews.; 1993
    Google Scholar
  • 34 Choyke PL, Glenn GM, Walther MM et al. Hereditary renal cancers. Radiology 2003; 226: 33-46
    CrossrefGoogle Scholar
  • 35 La Vecchia C, Bosetti C, Lucchini F et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2010; 21: 1323-1360
    CrossrefGoogle Scholar
  • 36 Albers P, Albrecht W, Algaba F et al. EAU guidelines on testicular cancer: 2011 update. European urology 2011; 60: 304-319
    CrossrefGoogle Scholar
  • 37 Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. The Journal of urology 2003; 170: 5-11
    CrossrefGoogle Scholar
  • 38 Germa-Lluch JR, Garcia del Muro X, Maroto P et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). European urology 2002; 42: 62-63
    Google Scholar
  • 39 Kim W, Rosen MA, Langer JE et al. US MR imaging correlation in pathologic conditions of the scrotum. Radiographics: a review publication of the Radiological Society of North America 1239-1253
    Google Scholar
  • 40 Recommendations of the National Cancer Institute and the National Institute of health on routine screening for testicular cancer. http://www.cancer.gov/cancertopics/pdq/screening/testicular/Patient/page3
    Google Scholar
  • 41 Tilki D, Burger M, Dalbagni G et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. European urology 2011; 60: 484-492
    CrossrefGoogle Scholar
  • 42 Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Current opinion in urology 2008; 18: 1-8
    CrossrefGoogle Scholar
  • 43 Mowatt G, Zhu S, Kilonzo M et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health technology assessment 2010; 14
    Google Scholar
  • 44 Warren KS, McFarlane J. The Bosniak classification of renal cystic masses. BJU international 2005; 95: 939-942
    CrossrefGoogle Scholar